256 related articles for article (PubMed ID: 12901581)
1. Emerging issues in vaccine economics: perspectives from the USA.
Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
[TBL] [Abstract][Full Text] [Related]
2. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
[TBL] [Abstract][Full Text] [Related]
4. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
5. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine.
Isakbaeva ET; Musabaev E; Antil L; Rheingans R; Juraev R; Glass RI; Bresee JS
Vaccine; 2007 Jan; 25(2):373-80. PubMed ID: 16930784
[TBL] [Abstract][Full Text] [Related]
6. Increasing adolescent vaccination: barriers and strategies in the context of policy, legal, and financial issues.
Ford CA; English A; Davenport AF; Stinnett AJ
J Adolesc Health; 2009 Jun; 44(6):568-74. PubMed ID: 19465321
[TBL] [Abstract][Full Text] [Related]
7. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines.
Widdowson MA; Steele D; Vojdani J; Wecker J; Parashar U
J Infect Dis; 2009 Nov; 200 Suppl 1():S1-8. PubMed ID: 19817589
[TBL] [Abstract][Full Text] [Related]
8. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
10. Health economic research on vaccinations and immunisation practices--an introductory primer.
Szucs TD
Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
[TBL] [Abstract][Full Text] [Related]
11. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
[TBL] [Abstract][Full Text] [Related]
12. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.
Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD
J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595
[TBL] [Abstract][Full Text] [Related]
13. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
Ault K; Reisinger K
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S26-8. PubMed ID: 18162242
[TBL] [Abstract][Full Text] [Related]
14. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
[TBL] [Abstract][Full Text] [Related]
15. Universal influenza vaccination in the United States: are we ready? Report of a meeting.
Schwartz B; Hinman A; Abramson J; Strikas RA; Allred N; Uyeki T; Orenstein W
J Infect Dis; 2006 Nov; 194 Suppl 2():S147-54. PubMed ID: 17163388
[TBL] [Abstract][Full Text] [Related]
16. [Introduction of vaccination against human papillomavirus in developing countries: update and perspectives].
Hessel L
Med Trop (Mars); 2009 Aug; 69(4):323-6. PubMed ID: 19725378
[TBL] [Abstract][Full Text] [Related]
17. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
18. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
[TBL] [Abstract][Full Text] [Related]
19. [Vaccination--value for money?].
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
[TBL] [Abstract][Full Text] [Related]
20. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
